In its effort to ward off a $53 billion hostile takeover, Allergan Inc. allegedly made false and misleading statements about Valeant Pharmaceuticals International Inc.’s business over the past few months, Valeant reported to the Securities and Exchange Commission and regulators in Canada.

Valeant, a Canadian drugmaker that teamed up with activist investor Bill Ackman in its bid for Allergan in April, accused Allergan of trying to mislead investors and manipulate the market for Valeant common shares by continuing to make false statements even after Valeant corrected the information.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]